![]() The researchers showed in mice that the tumor is destroyed by the drug-mediated inactivation of the oncogene, but that the tumor vasculature and thus the blood The aim of tumor therapy is to kill all cancer cells to prevent the recurrence of cancer disease. ![]() The tumor is then considered “established”. Only then, according to the researchers, is the development of the tumor tissue (tumor stroma), which also includes the tumor vasculature, complete. Moreover, a special feature of the study was that the tumors in the mice were large – bigger than one centimeter and containing about one billion cancer cells, comparable Thus, for the first time the effect of the two completely different therapy approaches could be compared directly with each other. Since the oncogene is also present as antigen on the surface of the tumor cells, the researchers were also able to target these tumors with oncogene-specific T cells. The researchers were thus able to target and inactivate the oncogene using the antibiotic drug doxycycline (dox), which has an effect similar to modern drugs currently in clinical use. The researchers transplanted tumor cells into mice that express SV40 large T antigen (Tag), the oncogene that is critical for tumor growth. The researchers hope that their insights in defining optimal conditions for T cell therapy may help improve future clinical trials and thus the treatment of cancer patients (Cancer Cell, doi10.1016/j.ccr.2011.10.019)*. Consequently, quasi as a side effect, “escapee” mutant tumor cells are eradicated that have become resistant to drug-based treatment and are responsible for tumor recurrence. However, the T cells not only kill cancer cells – they additionally destroy the tumor blood vessel system, thus impeding the supply of nutrients to the tumor. The researchers showed that both forms of therapy are highly effective against large tumors. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. ![]() This work is part of an ongoing 15 year study of familial dilated cardiomyopathy brought to the Miller School of Medicine in 2007 by Ray Hershberger, MD, professor of medicine and associate chief of the Cardiovascular Division.In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. “It’s truly amazing to see just how fast research has transformed with these tools and I’m proud to see that SeqWright has stayed ahead of the community as we adopt these technologies almost as fast as they are developed.” By being able to efficiently characterize the entire human exome, researchers can accelerate their research by taking the ‘candidate gene’ approach to a completely new level,” stated Fei Lu, M.D., CEO of SeqWright. “Sequencing the entire coding portion of the human genome has not been feasible until recent advancements in next generation genomic tools. The complete solution from Roche allows targeted re-sequencing of all of the coding exons, called the human exome, representing the portion of the human genome that is transcribed and translated into the myriad of proteins that function within all cells in the human body. SeqWright is sequencing the enriched exons to detect genetic variants within these samples, including single nucleotide polymorphisms (SNP’s) and insertions and deletions. In this collaboration SeqWright used NimbleGen Sequence Capture Human Exome Arrays to enrich over 180,000 exons from DNA samples from individuals affected with dilated cardiomyopathy. The research focuses on a major study to help identify possible genetic variants associated with dilated cardiomyopathy, a disease of heart muscle. Utilizing next generation sequencing and the latest advancements in sequence capture, SeqWright has announced a collaboration with Roche Applied Science and the University of Miami Miller School of Medicine.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |